National Institutes of Health: Glomerulosclerosis, Focal Segmental trials

The registry lists 11 Glomerulosclerosis, Focal Segmental studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 7Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte DiseasesRecruitingNCT06664814Phase 2
• Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)CompletedNCT00135811Phase 3Results posted
• Podocyte RetinoidsCompletedNCT00098020Phase 2Results posted
• Permeability Factor in Focal Segmental GlomerulosclerosisCompletedNCT00007475Phase 1/2Results posted
• Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)CompletedNCT00001959Phase 2Results posted
• Rituximab Treatment of Focal Segmental GlomerulosclerosisWithdrawnNCT00550342Phase 2
• Evaluation of Albuminuria HIV-Infected PatientsCompletedNCT00524992
• Kidney Disease BiomarkersCompletedNCT00255398
• Sirolimus for Focal Segmental GlomerulosclerosisCompletedNCT00040508Phase 2
• Once-A-Month Steroid Treatment for Patients With Focal Segmental GlomerulosclerosisCompletedNCT00004990Phase 2
• Genetic Markers for Focal Segmental GlomerulosclerosisCompletedNCT00001393